Clinical trial
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With…
NCT00070590 · Actelion, Industry · Completed
Key facts
| NCT number | NCT00070590 |
|---|---|
| Title | Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma |
| Official title | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis |
| Lead sponsor | Actelion, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Fibrosis, Scleroderma, Systemic |
| Intervention type | Drug |
| Interventions | Bosentan |
| Enrollment | 132 |
| Start date | Jul 1, 2003 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Oct 8, 2003 |
| Last update posted | Feb 3, 2025 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: